pegylated interferon alfa-2a + pegylated interferon alfa-2b

Pegylated interferon alfa-2a and pegylated interferon alfa-2b are long-acting forms of recombinant human alpha-interferons, modified by the attachment of polyethylene glycol (PEG) to extend their half-life in the body. Both drugs are classified as antiviral cytokines and are used primarily for the treatment of chronic hepatitis C infection, often in combination with other antivirals such as ribavirin. Peginterferon alfa-2a is also approved for chronic hepatitis B infection. Their mechanism involves binding to type 1 interferon receptors on cell surfaces, activating intracellular signaling pathways that induce an antiviral state, inhibit viral replication, and modulate immune responses against infected cells[1][3][4][5]. These agents were developed to improve dosing convenience and efficacy compared to non-pegylated forms.

Brand names

PegasysPegasys ProClick AutoinjectorPegasys Prefilled SyringePEG-Intron